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120 The Journal of Thoracic and CardioObjective: Laser transmyocardial revascularization is an emerging therapy for
intractable angina stemming from diffuse, small-vessel coronary disease not ame-
nable to percutaneous coronary intervention or coronary bypass grafting. Presently,
this therapy is delivered through a median sternotomy or left thoracotomy. In this
pilot study, we sought to combine the advantages of a dexterous robotic surgical
platform with a flexible fiberoptic laser to develop a minimally invasive approach
toward transmyocardial revascularization.
Methods: A flexible fiberoptic holmium:yttrium-aluminum-garnet laser probe (Car-
dioGenesis Corporation, Foothill Ranch, Calif), deployed with the da Vinci surgical
robotic system (Intuitive Surgical, Sunnyvale, Calif), was used to create transmyo-
cardial channels through all left ventricular wall regions in 5 canine subjects. The
channels were localized, quantified, and histologically analyzed to assess distribu-
tion, dimensions, and transmurality.
Results: Transmyocardial channels were successfully created in all 6 defined left
ventricular wall segments by using this minimally invasive approach without port
repositioning, instrument exchange, or probe modifications. Gross pathologic and
histologic analyses confirmed the uniform distribution of 1.0-mm transmural chan-
nels in all left ventricular regions. No direct pressure, topical hemostatic agents, or
suture repairs were required for hemostasis. No significant hemodynamic instability
or sustained arrhythmias were encountered at any time during the procedures.
Conclusions: We report the first use of a prototype flexible fiberoptic laser probe
deployed by the da Vinci surgical robotic system to successfully perform totally
endoscopic off-pump transmyocardial revascularization in a canine model, demon-
strating the feasibility, precision, and safety of this approach. Refinement of this
minimally invasive technique may reduce the morbidity of open-chest transmyo-
cardial revascularization and facilitate its use as sole therapy or as an adjunct to
percutaneous coronary interventions.
Although coronary artery bypass grafting (CABG) and percutaneous coro-nary interventions (PCIs) are proven therapies for relief of angina stemmingfrom ischemic heart disease, there exists a subset of “no-option” patients
with intractable angina caused by diffuse, small-vessel coronary disease not ame-
nable to these modalities. Transmyocardial laser revascularization (TMR) has
shown some clinical promise in substantially reducing anginal symptoms in these
patients either as sole therapy or in conjunction with CABG.1-5 Most recently, Allen
and colleagues6 also demonstrated a significantly reduced risk of late death for
no-option patients treated with sole-therapy TMR compared with maximal medical
therapy. TMR is currently delivered mainly through a median sternotomy or left
thoracotomy. In this study, we sought to combine the unique dexterity afforded by the
da Vinci surgical robotic platform with a prototype flexible fiberoptic holmium:yttrium-
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ETaluminum-garnet (Ho:YAG) laser TMR device (CardioGen-
esis Corporation, Foothill Ranch, Calif) to perform totally
endoscopic off-pump TMR in a canine model. We hypoth-
esized that the dexterous characteristics of these 2 systems
would facilitate the minimally invasive creation of TMR
channels in all segments of the left ventricle.
Materials and Methods
Adult mongrel dogs of either sex (n  5), weighing between 35
and 40 kg, were used in this experiment under a protocol approved
by the Johns Hopkins University Animal Care and Use Committee
(Protocol No. DO04M125) on May 11, 2004. All animals received
humane care in compliance with the “Principles of Laboratory
Animal Care” formulated by the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Figure 1. Prototype 1.0-mm CardioGenesis CrystalFlex fiberoptic
probe (top) fitted to the commercially available SoloGrip III TMR
holmium:yttrium-aluminum-garnet (Ho:YAG) laser handpiece (bot-
tom) (TMR2000; CardioGenesis Corporation, Foothill Ranch, Calif).Animals” prepared by the National Academy of Sciences and
The Journal of Thoracipublished by the National Institutes of Health (National Institutes
of Health Publication No. 85-23, revised 1985). Anesthetic induc-
tion was composed of intravenous thiamylal 10 mg/kg followed by
Kottmeier double-lumen endobronchial intubation (Rusch, Duluth,
Ga) and inhalational anesthesia with isoflurane (1%-2%). Each
animal was placed in a modified right lateral decubitus position
and subjected to selective right-lung ventilation. Systemic arterial
pressure was monitored with a femoral arterial line, and venous
access was obtained peripherally. Continuous electrocardiographic
telemetry and pulse oximetry (V3404 Plus, SurgiVet Inc, Wauke-
sha, Wis) were used.
The da Vinci surgical robotic system (Intuitive Surgical,
Sunnyvale, Calif) was used to perform the endoscopic TMR op-
erations. A 0-degree videoscope was introduced into the left tho-
racic cavity through a 12-mm port (United States Surgical Corp,
Norwalk, Conn) placed in the seventh intercostal space along the
Figure 2. Surgeon’s views through the da Vinci system (Intuitive
Surgical, Sunnyvale, Calif) master console of robot-assisted, en-
doscopic transmyocardial revascularization. Transmural chan-
nels were created through the anterior (top), anterolateral, apical,
posterolateral, posterobasal, and inferior (bottom) walls of the
beating canine left ventricle. Note the preserved left phrenic
nerve (bottom).midscapular line. Two 5-mm da Vinci instrument ports were
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ETplaced in the fifth and ninth intercostal spaces along the posterior
scapular line. Finally, a 5-mm “working” port (United States
Surgical Corp) was placed in the seventh intercostal space 4 cm
posterior to the videoscopic port. The left thoracic cavity was
insufflated with CO2 to pressures ranging from 5 to 10 mm Hg, and
the da Vinci “slave” device was docked to the ports. A da Vinci
DeBakey forceps and spatula electrocautery were used to create 2
transverse pericardiotomies, running 1 to 2 cm anterior and pos-
terior to the left phrenic nerve and extending from base to apex. All
wall segments of the left ventricle were easily exposed by grasping
the pericardial edges with a single forceps.
A prototype modification of the SoloGrip III TMR Ho:YAG
laser handpiece (TMR2000; CardioGenesis Corporation) fitted
with a 1.0-mm CardioGenesis CrystalFlex fiberoptic probe (Figure
1) was introduced into the left thoracic cavity through the working
port and grasped by 1 of 2 da Vinci DeBakey forceps instruments
under videoscopic guidance. Robot-assisted, endoscopic TMR was
used to create transmural channels through the anterior, anterolat-
eral, apical, posterolateral, posterobasal, and inferior walls of the
beating left ventricle at a density of approximately 1 channel/cm2
(Figure 2). The laser energy delivered to the myocardium consisted
of 7 watt pulses at a 5 Hz repetition rate with a pulse width of 200
sec (25%). The flexible probe was easily maneuverable by the
da Vinci instrumentation, and the cupped tip was gently placed on
each targeted area, oriented perpendicularly to the epicardial sur-
face without deforming or compressing the left ventricle. Once the
probe tip was seated on the epicardial surface, each channel was
created by the tableside surgeon by advancing the CrystalFlex
fiber, with the SoloGrip handpiece, through the myocardium while
discharging the laser pulses through it. Detection of transmural
penetration was achieved with auditory feedback to the tableside
surgeon. The number of pulses required to create each channel and
the number of channels created per ventricular region were re-
Figure 3. Representative histologic analysis of a transmyocardial
channel created with the robot-assisted, minimally invasive da
Vinci-CardioGenesis approach. This analysis confirmed the uni-
form creation of 1.0-mm transmural channels in all sampled
regions (hematoxylin-eosin stain, 5 magnification).corded. A 30-second pause was taken for ventricular recovery after
122 The Journal of Thoracic and Cardiovascular Surgery ● Julyeach group of 10 channels was created. No direct pressure, topical
hemostatic agents, or suture repairs were used for any channels.
The average operative time, from the initial port placement to the
completion of all TMR channels, was 38 minutes.
After the completion of each procedure, each animal was
observed for 30 minutes for hemodynamic stability and channel
hemostasis. After this period, each animal was euthanized by
hyperkalemic cardioplegic arrest under deep inhalational isoflu-
rane anesthesia. A left lateral thoracotomy was performed;
channel placement was quantified, localized, and documented;
and the hearts were explanted and fixed in 10% formalin. All
experiments were videotaped, and gross pathologic inspection
was performed. Targeted myocardial regions were excised and
underwent hematoxylin-eosin staining to assess channel distri-
bution, dimensions, and transmurality.
Results
Each of the 5 animal subjects survived robot-assisted endo-
scopic TMR. No significant hemodynamic instability or
sustained arrhythmias were encountered in any animal sub-
ject. As observed with conventional TMR, channel hemo-
stasis occurred spontaneously within several minutes after
the creation of the channels, without the need for direct
pressure, topical hemostatic agents, or suture closure. No
antiarrhythmics, inotropes, blood products, or intravenous
fluid boluses were required. Under excellent 3-dimensional
videoscopic guidance afforded by the da Vinci system, no
epicardial vessels were lacerated with the TMR device. For
each channel created, an angle of attack perpendicular to the
epicardial plane was readily achievable in all major regions
of the left ventricle without port repositioning, instrument
exchange, or probe modifications. Approximately 20 to 30
pulses were required to traverse the myocardium. Gross
pathologic and histologic analyses confirmed the uniform
creation of 1.0-mm transmural channels in all sampled
regions (Figure 3). The mean number of channels created in
each ventricular region is shown in Table 1.
Discussion
In 1933 Wearn and associates7 first described the arteriolu-
TABLE 1. Average number of channels created in each
ventricular region by endoscopic robot-assisted transmyo-
cardial revascularization
Left ventricular wall region treated
with endoscopic robot-assisted TMR
Mean number of TMR
channels created  SD*
Anterior 9.0  1.8
Anterolateral 7.3  1.2
Apical 5.2  0.7
Posterolateral 6.4  0.9
Posterobasal 8.0  2.1
Inferior 6.7  1.1
TMR, Transmyocardial revascularization. *Five canine subjects.minal vessels and intramyocardial sinusoids, which com-
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ETmunicate freely with the ventricular cavity. That led to the
development of TMR as a means of revascularizing isch-
emic myocardium by channeling oxygenated blood within
the left ventricular cavity into sinusoidal networks serving
ischemic regions. Although this mechanism has largely
been disproven,8-12 significant angina relief observed in
nonrandomized TMR trials led to several prospective, ran-
domized 1-year follow-up studies demonstrating angina re-
lief, improved exercise tolerance, decreased rehospitaliza-
tions, and improved event-free survival for no-option
patients with disabling severe angina refractory to medical
management and not amenable to CABG or PCI.1-5 Re-
cently, in a 5-year prospective, randomized, multicenter
trial, Allen and colleagues6 demonstrated sustained long-
term angina relief and increased survival in no-option pa-
tients receiving primary TMR versus medical therapy.
Currently, most patients receive TMR in conjunction
with CABG or after failed CABG through a median ster-
notomy or left thoracotomy, targeting myocardial regions
not amenable to bypass grafting or PCI.13 Far fewer no-
option patients undergo sole TMR as an initial surgical
procedure, presumably because of a lingering, yet healthy
skepticism as to the efficacy of TMR given the following:
(1) the lack of a definitive mechanism of action, (2) a
perceived placebo effect that has not been strictly excluded
in past clinical trials, because of the impracticality of a true
surgical “sham” group, and (3) no benefit seen in sham-
controlled, randomized studies using percutaneous myocar-
dial laser revascularization.14 Furthermore, diminished sur-
vivals have been observed with sole-therapy TMR applied
to patients in congestive heart failure or with poor ventric-
ular function.15 In this context, few cardiologists and car-
diac surgeons are willing to impose the morbidity of a
formal thoracotomy or median sternotomy (eg, pain, wound
healing, disfigurement) in delivering sole-therapy TMR as
an initial operation or even as an adjunct to PCI. To reduce
the morbidity-to-benefit ratio of sole-therapy TMR, ap-
proaches for minimally invasive TMR have been proposed.
deGuzman and colleagues16 described the conventional tho-
racoscopic application of CO2 laser TMR in pigs. Izutani
and colleagues17 used the Zeus robotic surgical system
(Computer Motion, Goleta, Calif) to perform excimer laser
(Xe:Cl) TMR in pigs. Although successful to varying de-
grees, these early attempts could not deliver TMR to all left
ventricular regions or required port relocation, instrument
exchanges, and/or manual handpiece angle adjustments to
do so.
We sought to develop a new minimally invasive, totally
endoscopic off-pump approach to TMR, facilitated by a
dexterous surgical robotic platform, to more easily deliver
TMR to all left ventricular wall regions. The da Vinci
surgical robotic system provides wrist-like dexterity and
superb stereoscopic visualization within the chest cavity.
The Journal of ThoraciWe have modified the commercially available CardioGen-
esis SoloGrip III Ho:YAG fiberoptic laser probe, permitting
it to be introduced into the chest cavity through a 5-mm
thoracoscopic port and easily manipulated across a wide
range of angles by the da Vinci instrumentation. We se-
lected the Ho:YAG laser over other commercially available
CO2 lasers because with the latter, laser energy is not
transmitted fiberoptically, but rather through relatively fixed
reflective elements. Combining the da Vinci system’s ro-
botic dexterity with the Ho:YAG laser’s flexible fiberoptic
conduit greatly facilitates positioning the probe at the pre-
cise location and perpendicular orientation to all left ven-
tricular regions for optimal TMR channel creation. Al-
though we believe this approach compares favorably with
conventional thoracoscopic techniques in this regard, we
did not perform the same procedure with standard thoraco-
scopic instruments to make objective comparisons.
Histologic and gross confirmation of transmural channel
penetration and distribution in all left ventricular wall seg-
ments were achieved in this study. The excellent visualiza-
tion and precise maneuverability afforded by this approach
also reduces the chance of inadvertent injury to epicardial
vessels. In more than 200 channels created in these exper-
iments, no epicardial vessel was lacerated.
Single-lung ventilation with gentle CO2 insufflation
greatly facilitates off-pump exposure of the heart for this
totally endoscopic approach. In turn, avoiding hepariniza-
tion associated with cardiopulmonary bypass greatly pro-
motes hemostasis. In these pilot studies, uniform spontane-
ous channel hemostasis without the aid of direct pressure,
topical hemostatic agents, or suture closure was achieved.
Furthermore, no sustained arrhythmias or hemodynamic
instability was noted in any of the preparations. We recog-
nize that this stability may not always be afforded by an
ischemic ventricle; therefore, we anticipate the mandatory
use of external defibrillator pads and cardiopulmonary by-
pass standby for this closed-chest approach.
Finally, we recognize that most animal models do not
anatomically replicate the human thorax; however, we did
find that, in our canine preparation, the left ventricle lies
within several centimeters to the chest wall, as it does in
humans with dilated cardiomyopathies. Despite this, we
were able to easily direct the TMR probe to all left ventric-
ular regions. This is an advantage afforded by our robotic
approach and may prove to obviate the need for additional
exposure devices used in other off-pump operations.
In summary, we describe our early experimental experi-
ence with a totally endoscopic, robot-assisted off-pump
approach for delivering TMR therapy. By combining the
advantages of a dexterous robotic surgical system with a
prototypic modification of a commercially available flexible
fiberoptic Ho:YAG TMR system, we demonstrate the fea-
sibility, precision, and safety of this approach. The targeted
c and Cardiovascular Surgery ● Volume 130, Number 1 123
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ETaims of this strategy are to substantially reduce the morbid-
ity of TMR therapies arising from open-chest approaches
and to facilitate the minimally invasive application of TMR
as initial sole therapy or as an adjunct to primary PCI,
addressing ischemic myocardial regions supplied by non-
stentable coronary arteries. Further developmental studies
appear to be warranted.
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